Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmune Bio Inc (NQ: INMB )

6.460 +0.450 (+7.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56,200
Open 6.030
Bid (Size) 6.000 (1)
Ask (Size) 6.800 (3)
Prev. Close 6.010
Today's Range 6.030 - 6.620
52wk Range 4.629 - 10.75
Shares Outstanding 17,703,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INmune Bio Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Earnings Preview: INmune Bio
 
Via Benzinga

Performance

YTD
-3.73%
-3.73%
1 Month
-31.57%
-31.57%
3 Month
-3.73%
-3.73%
6 Month
+5.38%
+5.38%
1 Year
-22.82%
-22.82%

More News

Read More
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
From INmune Bio, Inc.
Via Globe NewsWire
Dow Jumps 250 Points; US Jobless Claims Increase Last Week
Via Benzinga
Nasdaq Tumbles 150 Points; Crude Oil Up 1.5%
Via Benzinga
What to Know About the Future of Cancer Treatment
Via StatePoint Media
INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines
Via Benzinga
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
From INmune Bio, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease
From INmune Bio, Inc.
Via Globe NewsWire
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
From INmune Bio, Inc.
Via Globe NewsWire
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
From INmune Bio, Inc.
Via Globe NewsWire
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer
From INmune Bio, Inc.
Via Globe NewsWire
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
From INmune Bio, Inc.
Via Globe NewsWire
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease
From INmune Bio, Inc.
Via Globe NewsWire
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
From INmune Bio, Inc.
Via Globe NewsWire
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
From INmune Bio, Inc.
Via Globe NewsWire
Recap: INmune Bio Q2 Earnings
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
A Preview Of INmune Bio's Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.